Laura Feldman (Feldman & Pinto) and other Plaintiffs’ Attorneys File Petition to Consolidate Invokana Drug Injury Actions
According to a recent article in the Legal Intelligencer (titled Invokana Plaintiffs Seek to Consolidate Litigation), Attorney Laura Feldman of Feldman & Pinto, and other attorneys who commenced Invokana drug injury actions in the Philadelphia Court of Common Pleas, filed a petition on September 23, 2016, seeking to consolidate the claims into a mass tort program. The actions are brought against defendants Janssen Pharmaceuticals and Mitsubishi Tanabe Pharma, alleging that the diabetes drug Invokana caused plaintiffs’ diabetic ketoacidosis (through a buildup of acids in the blood) and kidney failure.
According to attorney Laura Feldman, the timing of the petition is right, given the large group of essentially identical claims and the efficiency that will result from consolidation. (The petition notes that 87 separate Invokana cases are pending in Philadelphia. The plaintiffs’ firms involved in the litigation expect this number to double within a short period of time.) The petition states: “In addition to significant financial savings, consolidation of these cases will promote the convenience of the parties and efficiency during pretrial proceedings, duplicative discovery will be eliminated, and there will be no risk of inconsistent judicial rulings.” Attorney Feldman also stated that the litigation could derive further benefit from management by Complex Litigation Center Coordinating Judge Arnold New.
Feldman & Pinto’s drug injury lawyers are currently evaluating cases from people who sustained personal injuries from the side effects of Invokana.